LINICAL NETHERLANDS B.V.

Their core work

Linical Netherlands (formerly Accelovance BV) is a contract research organization (CRO) providing clinical trial management and regulatory support for health and pharmaceutical projects. Within H2020 consortia, they contribute clinical development expertise — designing, running, and monitoring patient trials for therapeutic interventions. Their project portfolio spans hearing restoration therapies, immunological treatments, and cancer vaccine development, indicating broad clinical trial capabilities across multiple therapeutic areas.

What they specialise in

How they've shifted over time

All three projects were initiated in 2015-2016, so there is no meaningful temporal evolution within their H2020 portfolio. The projects ran concurrently rather than sequentially, suggesting the company was actively scaling its EU-funded clinical trial work during this period. Without later projects, it is unclear whether they continued pursuing EU research funding after 2016 or shifted focus to commercial CRO contracts.

Their H2020 activity concentrated in 2015-2016 with no later projects, suggesting either a strategic pivot away from EU-funded research or consolidation under the Linical brand for commercial contracts.

How they like to work

Linical Netherlands operates exclusively as a participant, never coordinating — consistent with a CRO providing specialized clinical trial services to research-led consortia. With 39 unique partners across 16 countries from just 3 projects, they plugged into large, multinational consortia. This suggests they are brought in for their operational clinical expertise rather than driving the research agenda themselves.

Despite only three projects, they collaborated with 39 partners across 16 countries, reflecting participation in large clinical research consortia with broad European reach. Their network is wide but likely driven by consortium composition rather than repeat partnerships.

What sets them apart

As a CRO embedded in academic-clinical consortia, they bridge the gap between laboratory research and regulated clinical trials — a capability many research-heavy consortia lack internally. Their parent company Linical is a global CRO, giving this Dutch office access to international trial infrastructure. For consortium builders needing a partner to handle GCP-compliant trial execution, they offer a ready-made solution.

Highlights from their portfolio

• AML-VACCiN
  Largest funding share (€1M) and focused on an advanced immunotherapy approach — dendritic-cell vaccines for leukaemia — representing high-value clinical development work.
• GLORIA
  Long-running project (2015-2021) comparing glucocorticoid treatment strategies, indicating involvement in a substantial multi-year clinical effectiveness study.